Fig. 2 | British Journal of Cancer

Fig. 2

From: Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Fig. 2

Kaplan–Meier estimates of survival by potential predictive factor, with 95% Hall–Wellner confidence bands and numbers at risk. Overall survival by plasma level of a follicle-stimulating hormone, b interferon-gamma induced protein 10, c macrophage inflammatory protein-1 alpha, and d plasminogen activator inhibitor 1. CL=confidence limits; GAL=galunisertib; GEM=gemcitabine; No.=number; PLC=placebo

Back to article page